Immunotherapy in head and neck cancer: aiming at EXTREME precision

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F17%3A00068012" target="_blank" >RIV/65269705:_____/17:00068012 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/17:00099900

Result on the web

<a href="https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0879-4" target="_blank" >https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0879-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12916-017-0879-4" target="_blank" >10.1186/s12916-017-0879-4</a>

Result language

angličtina

Original language name

Immunotherapy in head and neck cancer: aiming at EXTREME precision

Original language description

Background: Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic treatment often forms an integral part of their management. Immunotherapy is based on functional restoration of the host immune system, helping to counteract various tumour evasion strategies. Broadly, immunotherapeutic approaches encompass tumour-specific antibodies, cancer vaccines, cytokines, adoptive T-cell transfer, and immune-modulating agents. Until 2015, the epidermal growth factor receptor inhibitor cetuximab, a tumour-specific antibody, represented the only Food and Drug Administration (FDA)-approved targeted therapy for SCCHN. Subsequently, in 2016, the results from two prospective trials employing the immune-modulating antibodies nivolumab and pembrolizumab heralded a new era of anticancer treatment. Discussion: Nivolumab and pembrolizumab are monoclonal antibodies against programmed cell death protein-1 (PD-1), an &apos;immune checkpoint&apos; receptor. Found on the surface of T-cells, PD-1 negatively regulates their activation and can thus be exploited during carcinogenesis. The second-line phase III trial CheckMate-141 randomly assigned 361 patients with recurrent and/or metastatic SCCHN in a 2: 1 ratio to receive either single-agent nivolumab (3 mg/kg intravenously every 2 weeks) or standard monotherapy (methotrexate, docetaxel, or cetuximab). Nivolumab improved the objective response rate (13% versus 6%) and median overall survival (OS; 7.5 versus 5.1 months, p = 0.01) without increasing toxicity. Exploratory biomarker analyses indicated that patients treated with nivolumab had longer OS than those given standard therapy, regardless of tumour PD-1 ligand (PD-L1) expression or p16 status. In the non-randomised, multicohort phase Ib study KEYNOTE-012, treatment with pembrolizumab achieved comparable results.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BMC Medicine

ISSN

1741-7015

e-ISSN

—

Volume of the periodical

15

Issue of the periodical within the volume

JUN

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

110

UT code for WoS article

000402715100002

EID of the result in the Scopus database

—